July 10th 2024
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
San Diego Lung Symposia
September 7, 2024 - September 8, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate
Highlight on the debate format, speakers, and direction to support the discussion.
EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
November 27th 2023Experts discuss the rapidly evolving treatment landscape for EGFR exon 20 insertion lung cancer, highlighting recent advancements in therapies, clinical trial results, and the quest for first-line treatment options, providing valuable insights into managing this unique patient population.
Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations
November 27th 2023Sai-Hong Ou, MD, PhD, and Janellen Smith, MD, discuss the management of a patient with non-small cell lung cancer and an EGFR exon 20 insertion mutation who experienced a rash while on treatment with amivantamab; they highlight the importance of continuous treatment and potential considerations for this patient group.
Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance
November 27th 2023Sai-Hong Ou, MD, PhD, discusses the challenging management of patients EGFR-mutant non-small cell lung cancer who develop resistance to EGFR tyrosine kinase inhibitors, emphasizing the importance of understanding the resistance mechanism to tailor treatment.
Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
November 27th 2023Learn about the latest developments in the treatment of lung cancer, focusing on EGFR mutations, antibody-drug conjugates (ADCs), targeted therapies, and biomarker-driven approaches to improve patient outcomes in various stages of the disease.
Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC
November 20th 2023Drs Janellen Smith and Misako Nagasaka discuss dermatological adverse events in patients with non-small cell lung cancer associated with EGFR tyrosine kinase inhibitors, offering advice on prevention, treatment, and when to involve a dermatologist.
EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
November 20th 2023Shared insight into the complexities in treating EGFR mutant lung cancer during the second-line therapy phase, including safety profiles of different treatment regimens, managing toxicities, and ongoing research to improve patient outcomes.
Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
November 20th 2023Experts consider the influence of combination therapies on EGFR-mutant lung cancer treatment, including the impact on central nervous system (CNS) response, challenges in CNS metastases management, and the potential alternatives to whole-brain radiation.
Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
November 13th 2023Explore significant updates in the field of EGFR-mutant lung cancer treatment, focusing on the introduction of combination therapy in the first-line setting, including the FLAURA2., MARIPOSA, and RAMOSE trials, offering improved progression-free survival and potential implications for patient care.
The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC
November 13th 2023Sai-Hong Ou, MD, PhD, discusses the rapidly evolving landscape of first-line therapy for sensitizing EGFR mutant non-small cell lung cancer, including potential combination therapies and the introduction of new treatment options, such as antibody drug conjugates.
Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC
November 13th 2023Dr Sai-Hong Ou and Dr Janellen Smith discuss the case of a 59-year-old patient with non-small cell lung cancer and an EGFR mutation who experienced severe diarrhea and acne form rash while on osimertinib, providing insights into managing these treatment-related side effects.
Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)
November 6th 2023In this program, Sai-Hong Ou, MD, PhD, discusses biomarker testing for precision medicine in non-small cell lung cancer, emphasizing the importance of both tissue and blood-based genotyping, and the need for a complementary approach due to potential limitations in detecting targetable mutations.
Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC
October 30th 2023Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.
Adjuvant Pembrolizumab Earns European Approval for High-Risk NSCLC
October 26th 2023Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.
Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation
October 23rd 2023Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.
Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC
October 16th 2023Kristen Neumann, DNP, FNP-C, highlights the value of a multidisciplinary approach in the care of patients with EGFR-mutated non-small cell lung cancer, emphasizing the roles of dermatologists, pharmacists, and nurses in ensuring thorough patient assessment and education; Misako Nagasaka, MD, PhD, highlights data from WCLC 2023 on osimertinib in EGFR-mutated NSCLC.
Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs
October 16th 2023Kristen Neumann, DNP, FNP-C, emphasizes the importance of early assessment and potential dose reductions or holds when patients on treatment for EGFR-mutated non-small cell lung cancer show adverse effects, while Misako Nagasaka, MD, PhD, stresses the need for accurate symptom history and supporting lab work to ensure patient safety.
Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC
October 9th 2023Kristen Neumann, DNP, FNP-C, and Misako Nagasaka, MD, PhD, discuss the importance of patient education on diarrhea as a side effect of EGFR-mutated non-small cell lung cancer treatment, emphasizing dietary considerations and the use of over-the-counter remedies.